NIOSH Hazardous Drugs

Table 1 Antineoplastic drugs

The National Institute for Occupational Safety and Health (NIOSH) considers a drug to be hazardous if it exhibits at least one of the following criteria: carcinogenicity, teratogencicity or developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or structure and toxicity profiles of new drugs that mimic existing hazardous drugs.

abiraterone	docetaxel	omacetaxine
ado-trastuzumab emtansine	doxorubicin	oxaliplatin
afatinib	enzalutamide	paclitaxel
altretamine	epirubicin	panobinostat
amsacrine	eribulin	pazopanib
anastrozole	erlotinib	pemetrexed
arsenic trioxide*	estramustine	pentostatin
axitinib	etoposide	pertuzumab
azacitidine	everolimus	pipobroman
Bacillus Calmette Guerin (BCG)	exemestane	pomalidomide
belinostat	floxuridine	ponatinib
bendamustine	fludarabine	pralatrexate
bexarotene	fluorouracil	procarbazine
bacalutimide	flutamide	regorafenib
bleomycin	fulvestrant	romidepsin
bortezomib	gemcitabine	sorafenib
bosutinib	gemtuzumab ozogamicin	streptozocin
brentuximab vedotin	goserelin	sunitinib
busulfan	histrelin	tamoxifen
cabazitaxel	hydroxyurea	temozolomide
cabozantinib	idarubicin	temsirolimus
capecitabine	ifosfamide	teniposide
carboplatin	imatinib	thioguanine
carfilzomib	irinotecan	thiotepa
carmustine	ixazomib	topotecan
chlorambucil	ixabepilone	toremifene
cisplatin	letrozole	trametinib
cladribine	leuprolide	trifluridine/tipiracil (combination only)
clofarabine	lomustine	triptorelin
crizotinib	mechlorethamine	valrubicin
cyclophosphamide	megestrol	vandetanib
cytarabine	melphalan	vemurafenib
dabrafenib	mercaptopurine	vinblastine
dacarbazine	methotrexate	vincristine
dactinomycin	mitomycin	vinorelbine
dasatinib	mitotane	vismodegib
daunorubicin	mitoxantrone	vorinostat
decitabine	nelarabine	ziv-aflibercept
degarelix	nilotinib	

*P-Listed Waste. All trace P-Listed material must be managed as RCRA hazardous waste.

NIOSH Hazardous Drugs

Table 2 Non-Antineoplastic (one or more criteria)

The National Institute for Occupational Safety and Health (NIOSH) considers a drug to be hazardous if it exhibits at least one of the following criteria: carcinogenicity, teratogencicity or developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or structure and toxicity profiles of new drugs that mimic existing hazardous drugs.

Table 2 | **Non-Antineoplastic (one or more criteria)**

abacavir	fingolimod	phenytoin
alefacept	fluoxymesterone	progesterone
apomorphine	fosphenytoin	progestins
azathioprine	ganciclovir	propylthiouracil
carbamazepine	leflunomide	raloxifene
chloramphenicol	lenalidomide	rasagiline
cidofovir	liraglutide recombinant	risperidone
cyclosporine	medroxyprogesterone acetate	sirolimus
deferiprone	methimazole	spironolactone
dexrazoxane	mipomersen	tacrolimus
diethylstilbestrol	mycophenolate mofetil	teriflunomide
divalproex	mycophenolic acid	thalidomide
entecavir	nevirapine	tofacitinib
estradiol	ospemifene	uracil mustard
estrogen/ progesterone combinations	oxcarbazepine	valganciclovir
estrogens, conjugated	palifermin	zidovudine
estrogens, esterified	paliperidone	
estropipate	phenoxybenzamine	

*P-Listed Waste. All trace P-Listed material must be managed as RCRA hazardous waste.

NIOSH Hazardous Drugs

Table 3 Non-Antineoplastic (Reproductive Effects)

The National Institute for Occupational Safety and Health (NIOSH) considers a drug to be hazardous if it exhibits at least one of the following criteria: carcinogenicity, teratogencicity or developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or structure and toxicity profiles of new drugs that mimic existing hazardous drugs.

Table 3 | **Non-Antineoplastic (Reproductive Effects)**

acitretin	ganirelix	ribavirin
alitretinoin	gonadotropin, chorionic	riociguat
ambrisentan	icatibant	telavancin
bosentan	lomitapide	temazepam
cabergoline	macitentan	testosterone
cetrorelix	mentropins	topiramate
choriogonadotropin	methyltestosterone	tretinoin
clomiphene	mifepristone	ulipristal
clonazepam	misoprostol	valproate/valproic acid
colchicine	nafarelin	vigabatrin
dinoprostone	oxytocin	voriconazole
dronedarone	pamidronate	warfarin*
dutasteride	paroxetine	ziprasidone
eslicarbazepine	pasireotide	zoledronic acid
ergonovine/methylergonovine	pentetate calcium trisodium	zonisamid
finasteride	peginesatide	
fluconazole	plerixafor	

*P-Listed Waste. All trace P-Listed material must be managed as RCRA hazardous waste.